Pharma News

AstraZeneca plans to submit baxdrostat for regulatory review by the end of 2025, aiming for potential approvals in 2026 starting in the U.S. and EU.

Cytokinetics’ aficamten improved symptoms and cardiopulmonary performance more than metoprolol in a 175-patient head-to-head study of obstructive hypertrophic cardiomyopathy (oHCM), with detailed data unveiled at the ESC Congress (Madrid).

The U.S. FDA approved Sanofi’s BTK inhibitor Wayrilz (rilzabrutinib) to treat adult persistent or chronic immune thrombocytopenia (ITP) who failed prior therapies—a milestone from Sanofi’s $3.7B Principia acquisition.

Glenmark Pharmaceuticals has announced a voluntary recall in the US, pulling more than 88,000 bottles of Carvedilol (a high blood pressure drug) and 22,656 bottles of Theophylline (used for COPD) from the market.

A recent report from India’s Parliamentary Committee on Petitions warns that a large proportion of cancer medicines are still not subject to official price ceilings, leaving many treatments unaffordable for patients.

Danish pharma giant Novo Nordisk has confirmed the theft of six batches of its products—including insulin brands Ryzodeg and Fiasp, and weight-loss drug Wegovy—during transit from its Bhiwandi hub to several Indian cities.

On August 7, 2025, the European Food Safety Authority (EFSA) announced that oxygen (E 948) and hydrogen (E 949) remain safe as food additives across all food categories, including products for infants and young children.

On August 11, 2025, the European Food Safety Authority (EFSA) announced its expert panel has found no safety concerns for Vitamin E polyethylene glycol succinate (TPGS) as a food additive at proposed use levels.

India’s pharmaceutical sector is calling on the US government to exclude generic drug imports from a sweeping national security investigation that could trigger major supply disruptions and price spikes.

Haryana’s Narcotics Control Bureau is seeing unprecedented public backing in its ongoing battle against drugs, according to Director General O P Singh.

Glenmark Pharmaceuticals is aiming for 10–15% annual growth in its Indian business over the next two to three years, driven by a strong pivot to high-margin and branded products.

Analysts expect that upcoming oral obesity drugs from Eli Lilly and Novo Nordisk will launch in the US at prices similar to injectable blockbusters Wegovy and Zepbound—around $1,000 per month.

Eli Lilly has signed a $1.3 billion agreement with Superluminal Medicines to accelerate the discovery and development of AI-powered obesity treatments.

Eli Lilly will hike the UK list price of its weight-loss drug Mounjaro by a dramatic 170% starting September, pushing the monthly cost for the highest dose from £122 to £330.

The US FDA has granted approval to Precigen’s breakthrough immunotherapy, Papzimeos, for adults suffering from recurrent respiratory papillomatosis (RRP), a rare and potentially fatal disease caused by HPV infection.

Novo Nordisk has unveiled its breakthrough weight-loss drug Wegovy in South Africa, marking the therapy’s debut on the African continent amid soaring obesity rates.

Pfizer has raised its full-year profit outlook after a strong second quarter, driven by robust demand for its blockbuster heart drug Vyndaqel and the blood thinner Eliquis.

Swiss pharmaceutical company Sandoz has announced plans to launch generic weight-loss medications in Canada at discounts of up to 70% compared to current branded versions once patents start expiring next year.

Syndax Pharmaceuticals posted a second-quarter net loss of $71.8 million ($0.83 per share), exceeding last year’s $68.1 million loss, even as revenue from key therapies soared.

Vertex Pharmaceuticals’ bid to expand into non-opioid pain treatments was dealt a heavy blow as its next-generation drug VX-993 failed a critical mid-stage trial, triggering a sharp 14.4% after-hours share drop.